The cause of amyloidosis is unknown. Symptoms vary according to the organ or system affected by the disease, and on the size of amyloid deposits. Some patients may have no symptoms. Because of the ...

Early clinical diagnosis of an under-recognized form of amyloidosis that causes rapidly progressing polyneuropathy is crucial to improving patient outcomes. Worldwide, the most common mutation ...

A meta-analysis of 95 studies on the prevalence and all-cause mortality of all types of transthyretin amyloidosis (ATTR) ...

[Ash 2020;3c,5a] AL cardiac amyloidosis may also cause rhythm disturbances, and atrial fibrillation may develop as the amyloidosis progresses. [Ash 2020;5b] The pathophysiological manifestations ...

Almost four years after it was approved in Europe to treat the incurable rare disease systemic amyloid light-chain (AL) amyloidosis ... bone marrow disorder that causes amyloid to build up ...

The deal gives the Anglo-Swedish drugmaker complete control of Caelum's late-stage medicine for light chain (AL) amyloidosis, a potentially fatal disease that causes the rogue protein amyloid to ...

About AL Amyloidosis AL amyloidosis is caused by abnormal plasma cells in the bone marrow, which produce misfolded amyloid proteins that build-up in the heart, kidney, liver, and other organs. This ...

UK MHRA grants marketing approval for BridgeBio Pharma’s Beyonttra to treat ATTR-CM: Palo Alto, California Wednesday, April 30, 2025, 16:00 Hrs [IST] BridgeBio Pharma, Inc., a n ...

This classification of amyloidosis is thought to be autosomal dominant (only one copy of the defective gene is necessary to cause the disease). A child of a parent with hereditary amyloidosis has ...